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Abstract
In this study, we compared, for the first time, the release of a 432 kDa prostaglandin F2a analogue drug, Latanoprost, from
commercially available contact lenses using in vitro models with corneal epithelial cells. Conventional polyHEMA-based and
silicone hydrogel soft contact lenses were soaked in drug solution (131mg=ml solution in phosphate buffered saline). The
drug release from the contact lens material and its diffusion through three in vitro models was studied. The three in vitro
models consisted of a polyethylene terephthalate (PET) membrane without corneal epithelial cells, a PET membrane with a
monolayer of human corneal epithelial cells (HCEC), and a PET membrane with stratified HCEC. In the cell-based in vitro
corneal epithelium models, a zero order release was obtained with the silicone hydrogel materials (linear for the duration of
the experiment) whereby, after 48 hours, between 4 to 6 mg of latanoprost (an amount well within the range of the
prescribed daily dose for glaucoma patients) was released. In the absence of cells, a significantly lower amount of drug,
between 0.3 to 0.5 mg, was released, (pv0:001). The difference observed in release from the hydrogel lens materials in the
presence and absence of cells emphasizes the importance of using an in vitro corneal model that is more representative of
the physiological conditions in the eye to more adequately characterize ophthalmic drug delivery materials. Our results
demonstrate how in vitro models with corneal epithelial cells may allow better prediction of in vivo release. It also highlights
the potential of drug-soaked silicone hydrogel contact lens materials for drug delivery purposes.
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Introduction
Ocular drug delivery is either intended to target the ocular
surface to manage superficial conditions such as dry eye, microbial
keratitis and conjunctivitis, or to treat intraocular disorders such as
glaucoma, and age-related macular degeneration. Eye-drops are
still the most common drug delivery method, comprising 90% of
ophthalmic medications, followed by ointments and gels [1]. Eye-
drop medications are applied topically to the eye in the form of
either a solution or suspension in water [2]. The aqueous eye-drop
is rapidly diluted in the tear film and most of it is drained through
the lacrimal system, therefore, requiring frequent applications [3].
Studies show that only about 1 to 5% of the applied dose
penetrates the cornea [4] and that due to the relatively fast
turnover rate of the aqueous layer of the tear film, the residence
time of hydrophilic medications is around 2 to 5 minutes [5]. The
relatively slow turnover rate of the tear film lipid layer results in
their increased residence time for lipophilic drugs, which reside in
this layer, and consequently results in an increased uptake into the
eye. The purpose of topical ophthalmic drug delivery devices is to
deliver an adequate amount of medication to the anterior segment
of the eye, with accurate targeted dosing at a sustained and
controlled rate to increase bioavailability of the drug. Several
commercial ocular delivery devices are currently available,
including surface-located inserts [6], degradable or non-degrad-
able implants [7], and in situ forming gels [8]. Despite almost 50
years of research being conducted on the potential use of soft
contact lenses to deliver topical ophthalmic drugs [9], no drug
delivery contact lens has yet been commercialized [10].
It is accepted that simple ‘‘soaking’’ of a contact lens in a topical
drug solution may be insufficient for adequate elution on the
ocular surface; therefore, it is considered to have a low potential
for success [11,12]. Thus a variety of research efforts are
attempting to increase the drug uptake and/or release rates.
These have included prolonged (up to 2 weeks) soaking [13],
soaking the lenses in super-critical drug solutions [14], soaking the
dehydrated contact lenses in drug solutions [15], and using
vitamin E as a barrier to decrease diffusion of the drugs [16].
However, these efforts have resulted in minimal to no effect on the
elution time and release kinetics [11]. It has been documented that
the hydrophobic interactions of the active agents (i.e., drugs or
other compounds) with the contact lens material is the primary
governing factor in the adsorption and subsequent release of these
compounds [17].
For the most part, drug release has been studied in a fixed
volume of deionized water (DI), Phosphate Buffered Saline (PBS)
or artificial tear solutions [11]. In these studies, the drug-eluting
contact lens material is placed in a vial with a fixed volume of the
release solution, and samples are collected from the solution at
various time points. In fixed volume release studies, parameters
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such as the release medium and its volume, as well as mixing
condition, are critically important [11]. The amount of released
drug and the elution time have been shown to be consistently
smaller when tested using the in vitro fixed volume model
compared to in vivo experiments [12,14,18–23]. In the fixed
volume conditions, the drug release mechanism is governed by
diffusion, where concentration gradients generate the driving force
and the ratio of the concentration between the contact lens and the
medium is dictated by the partition ratio. The fixed volume
environment does not represent the ocular environment, where
there is a limited amount of tear liquid with a relatively fast tear
turnover. The composition of the release medium also plays an
important role in release studies. While a contact lens material
may present optimal release in DI-water, their performance might
be reduced dramatically in the presence of ions or surfactants [24].
In the field of contact lens drug delivery, the inadequacy of current
release models has limited progress, primarily by giving rise to a
false estimates of the kinetics of release, where the reported
behavior cannot be recreated in the physiologic environment.
Recently, Byrne et al. introduced a microfluidic device with the
purpose of generating physiological flow rates to study the release
rate through ophthalmic materials, thus generating a more
representative release environment [25]. This microfluidic device
mimics tear flow rate and the limited tear volume in the eye.
Considering that the primary drug permeation route to the
front of the eye is through the transcorneal pathways, it is also
important to consider the role of the cornea in drug release studies
[26]. The lipid bilayer cell membrane retards the permeation of
hydrophilic compounds. Through expressing certain transporters
as well as certain enzymes present in the epithelial cells, the cornea
is involved in metabolism and transportation of prodrugs and their
active metabolized form [27–31]. The corneal epithelium is
considered to be the rate-limiting factor in the transcorneal
permeation of most ophthalmic drugs [32,33], especially for
hydrophilic drugs [34,35]. Thus, using an in vitro corneal
epithelial model will allow replication of the relevant factors of
the in vivo environment. Human corneal in vitro models offer a
cost effective and more standardizable substitutes [36] for animal
studies while allowing a higher throughput testing of biomaterial
interaction and drug permeation [37]. Reconstructed corneal
equivalents as well as cell culture models of the corneal epithelium
have been successfully used to study ocular toxicity and
permeability [37–41].
Pharmacokinetics of most prostaglandin F2a analogues has been
extensively studied in vivo [4,42]. The contribution of the enzyme
and transport activities such as the esterase activity of the corneal
epithelium has been utilized in the design of ophthalmic prodrugs
[43]. The lipophilicity, as a result of esterification or amidification
of PGF2a analogues, facilitates the penetration through the cornea.
Prostaglandin analogues metabolism into the hydrophilic acid
forms inside the epithelial cells allows permeation through the
stroma [44] and thus, increases the bioavailability of the active
substance in the interior of the eye [45]. We therefore hypothesize
that the presence of corneal epithelial cells may have an impact
when assessing drug-delivery materials in vitro. The objective of
this study was to investigate the release of Latanoprost by
commercially available contact lenses using in vitro models
containing corneal epithelial cells.
Materials and Methods
Preparation of Drug Doping Solutions
The lens doping solution was prepared by dissolving latanoprost
and latanoprost free-acid (solution in methyl acetate, Cayman
Chemical, Ann Arbor, MI) in PBS (Lonza, Walkersville, MD). The
concentration of the stock drug solution was 131mg=mL.
Preparation of Contact Lenses
Four commercially available contact lens materials, galyfilcon
A, senofilcon A, omafilcon A, and balafilcon A were used. The
properties of the four lens types are presented in table 1. All lenses
had a back vertex power of 23.00 diopter. Lenses were incubated
for 24 hours in PBS (Lonza, Allendale, New Jersey) to remove any
remnants of their packaging solutions, before incubation in 1:5mL
of the drug solution for 24 hours.
In Vitro Cell Culture
HPV-immortalized human corneal epithelial cells, a generous
gift from Dr. May Griffith (Integrative Regenerative Medicine
(IGEN) Centre, Linko¨ping University, Sweden) [38] were cultured
in keratinocyte serum free medium (KSFM) supplemented with
bovine pituitary extract, recombinant epidermal growth factor,
and penicillin/streptomycin (Pen/Strep) (ScienCell, Carlsbad,
California, USA) at 370C and 5% carbon dioxide (CO2). Fresh
medium was added every other day and cells were grown to 90%
confluency in tissue culture treated flasks. Adherent cells were
removed using TryplExpress (Life Technologies, Burlington,
Ontario, Canada) dissociation solution. Cells were routinely
observed for any morphological changes and were used before
their eleventh passage.
In Vitro Drug Release Models
Three in vitro models were used to assess drug release from
commercially available contact lenses in-cluding diffusion through
a) a Polyethylene Terephthalate (PET) membrane (Millicell PET
membrane with a 1:0mm pore size, also referred to as culture
inserts, Millipore, MA, USA) with no-cells; b) a PET membrane
with a monolayer of human corneal epithelial cells (HCECs) and c)
a PET membrane with a multilayer of HCECs (stratified culture).
For the two latter models, the PET membranes were seeded with
105 cells. The corneal epithelium models were fed with KSFM on
each of the basal and apical sides of the cells layer for five days,
with medium being exchanged every other day. After five days, for
the multilayer models, cell differentiation was induced by exposing
the monolayer to an air-liquid interface. Cells were fed only on the
basal side with 2% fetal bovine serum (FBS, Invitrogen,
Burlington, ON, Canada) in 1:1 Dulbeccos minimum essential
medium (DMEM, Invitrogen) in Hams F12 nutrient medium
(DMEM/F12, Invitrogen); the medium was exchanged daily [41].
The cells grew under these conditions for seven days and were
then ready for experimentation.
Measuring Drug Concentrations
Aliquots of 100ml (10% of the total volume of the medium
present in the bottom) were taken from the bottom of the in vitro
models and replaced by fresh culture medium. For the latanaprost
experiments, samples were taken at 1, 3, 6, 12, 18, 24 and
48 hours. For latanoprost free-acid experiments, samples were
collected at 1, 3, 6, and 24 hours.
Collected samples were analyzed by an enzyme immuno-assay
(EIA) for latanoprost (Cayman Chemical, Ann Arbor, MI, USA).
Following the EIA kit instructions, each collected sample was
analyzed in duplicate and at two different dilutions. To determine
the uptake amount by the contact lenses, samples were also
aliquoted from the original drug stock solution as well as the
remaining drug solutions after soaking the lenses.
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The release results represent the concentration of the drug on
the other side of the PET membrane, meaning that the drug has
been released from the contact lens material on top of the
membrane, then diffused through the cells, if present, and the
culture membrane. Note that the EIA kit does not distinguish
between the free-acid form and ester form of the drug.
Drug Concentration Calculations
As mentioned above, to measure the amount of released drug,
samples were taken from the bottom of the wells and replaced by
fresh solution at each time point. Refreshing a fraction of the
medium in the bottom at each time point affects measurements.
Therefore, it is necessary to account for the dilution effect and
adjust the measured concentrations to provide an accurate
measure of the concentration without the dilution effect.
Assuming the fraction of total volume of medium in the bottom
which is being aliquoted is ‘‘k’’, the mass balance principle can be
used to estimate for the actual concentration at each time point.
mi~CiVb ð1Þ
mi,a~CiVbzk
Xi{1
j~1
CjVb ð2Þ
In Eq.(1), mi refers to the amount of drug at i-th time point (ti),
Ci refers to the measured concentration at time ti, and Vb is the
volume of the liquid in the bottom. An estimate of the actual
amount of drug diffused through the insert adjusted for the
dilution effect, ma,i , can be calculated using Eq.(2). This equation
can be obtained as below by calculating the accumulated drug
amount in the medium by adding the removed amount in previous
steps to the amount of the drug available in medium at each step.
ma,1~m1~VbC1 Dm1~kC1Vb
ma,2~m2zDm1~C2VbzkVbC1 Dm2~kC2Vb
ma,3~m3zDm2zDm1~C3Vbzk(C1zC2)Vb Dm3~kC3Vb
..
.
ð3Þ
The adjusted concentration, Ca,i at i-th step can be found as
below:
Ca,i~Cizk
Xi{1
j~1
Cj ð4Þ
The proposed method to estimate adjusted concentrations
neglects the effect that dilution might have on the diffusion rate.
However, for small difference between calculated and measured
concentrations, the change in diffusion rate will be insignificant.
Data Analysis
Results are presented as the mean of six experiments for
latanoprost and three experiments for latanoprost free-acid +
standard deviation. All experiments were performed on different
days. To evaluate the significance of the differences between
various contact lens materials, in vitro corneal models and time
points, an analysis of variance (ANOVA) was performed, followed
by multiple pair-wise comparisons using the Holm-Sidak test
(SigmaPlot, San Jose, California, USA).
Results
Preliminary studies showed that there was no decay of
latanoprost and latanoprost free-acid in the culture medium or
buffered solution used in the current research (results not
presented), thus enabling the use of the enzyme immuno-assay
method to measure drug concentrations in both solutions for up to
48 hours. All the results presented have also been adjusted
according to Eq. (4), to take into account the small dilution that
may occur as samples are taken out and fresh medium is added.
Table 1. Properties of the Contact Lens Hydrogel Materials [47].
Commercial name Acuvue Advance Acuvue Oasys ProClear PureVision
(US adopted name) Galyfilcon A Senofilcon A Omafilcon A Balafilcon A
Manufacturer Johnson & Johnson Johnson & Johnson Coopervision Bausch & Lomb
Water content 47 38 60 36
Principal Monomer mPDMS + DMA + HEMA+ siloxane
macromer+ EGDMA + PVP
mPDMS + DMA + HEMA + siloxane
macromer + TEGDMA + PVP
HEMA + PC NVP + TPVC + NVA + PBVC
V(I) V(I) II V(III)FDA group*
Low water Low water High water Low water
Non-ionic Non-ionic Non-ionic Ionic
*FDA (Food and Drug Administration) categorizes all silicone hydrogel contact lenses as group V, however it is more practical to use groups for conventional hydrogels
to better understand their material properties. HEMA, Hydroxyethyl Methacrylate; PC, Phosphotidylcholine; NVP, N-Vinylpyrrolidone; TPVC, Tris(trimethylsiloxysilyl)
Propyvinyl Carbamate; NVA, N-Vinyl Aminobutyric Acid; PBVC, Poly(dimethysiloxy)di (silylbutanol) Bis(Vinyl Carbamate); mPDMS, monofunctional Polydimethylsiloxane;
DMA, N, N-Dimethylacrylamide; EGDMA, Ethyleneglycol Dimethacrylate; PVP, Polyvinyl Pyrrolidone; TEGDMA, Tetra-Ethyleneglycol Dimethacrylate
doi:10.1371/journal.pone.0106653.t001
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The uptake analysis showed that 95% of the dissolved
latanoprost was taken up by the galyfilcon A and senofilcon A
silicone hydrogels and 98% by the balafilcon A (thus approxi-
mately 185mg=lens) and nearly 25% of the latanoprost solution
was taken up into omalfilcon A (50mg=lens).
Release in the absence of cells
In the no-cells model, release was first measured in KSFM to
allow for comparisons between all in vitro models. As shown in
Fig. 1, an initial burst in the first 6 hours was observed, followed
by saturation, when no more drug was released, despite the
available drug in the contact lens material.
The effects of the release medium was also assessed with the
three silicone hydrogel contact lens materials for 24 hours, where
the cell culture medium (KSFM) was substituted with PBS. When
compared to KSFM, the latanoprost release decreased signifi-
cantly in the no-cell model in PBS (pv0:001), Fig. 2.
Release in the presence of a monolayer or multilayer
model
Performing the contact lens release experiments in the presence
of corneal epithelial cells resulted in significant changes. As
illustrated in Fig. 3, the amount of latanoprost released from
senofilcon A was dependent on the presence of cells in the in vitro
models; a significantly higher amount of latanoprost was released
in the monolayer and multilayer models (pv0:001) when
compared to the no-cell model. Furthermore, while in the no-
cell model, no significant difference in release was observed over
time, for the monolayer and multilayer models, there was a
significant increase in the amount released at 1, 3, 12, 18, 24 and
48 hrs (pv0:05). For all contact lens materials studied, in the
monolayer and multilayer in vitro corneal models, an extended
release of drug was observed over time (Fig. 4). The improved
release profiles from latanoprost-soaked contact lenses was similar
between the monolayer and multilayer models (p~0:678).
The release results for all tested commercial contact lenses are
summarized in table 2. While the amount of drug released fell
within potential therapeutic ranges, only 2% of the amount of the
drug sorbed into silicone hydrogel contact lens material was
released after 24 hours (Table 2). A significantly higher amount
(between 10 to 17% depending on the model used) was released
from the high water content hydrogel material, omafilcon A. The
high release of latanoprost from omafilcon A (Fig. 4) is in spite of
the lower drug uptake, which results in a significantly higher
release percentage ((pv0:001), Table 2). Latanoprost release from
galyfilcon A and senofilcon A were not significantly different
(p~0:736) and neither were they different from the release
observed with balafilcon A (pw0:3).
Release of Latanoprost Free-Acid
Since in the absence of cells, latanoprost cannot be metabolized
to its free-acid form, the release of latanoprost free-acid from
contact lens materials was studied to determine if latanoprost free-
acid may be used as a substitute to latanoprost in a no-cell model.
To allow for a more complete comparison between models and
drug forms, release of latanoprost free-acid was also tested with the
same in vitro models.
With latanoprost free-acid, contrary to what was observed with
the ester form of the drug, a significantly lower release occurred in
the presence of cells when compared to no-cells (Fig. 5). Table 3
presents the release of latanoprost free-acid from tested commer-
cial contact lenses after 24 hours for each of the in vitro models.
When comparing the amount of drug release at 24 hours in the
monolayer model, the latanoprost free-acid results show a
significant decrease (approximately 30%) in the amounts of the
drug that has been released from galyfilcon A and senofilcon A
silicone hydrogels (Table 2).
Figure 1. Time course of latanoprost release from four contact lens materials through the no-cells model. Lenses were soaked for
24 hours in drug solution (131mg=mL) and then overlayed on the model for 24 hours. Aliquots were taken at specific times from the lower
compartment and concentrations was measured using EIA. Daily dose line represents the amount of the administered latanoprost for a glaucoma
patient [46]. *Significantly different from silicone hydrogel contact lens materials (pv0:001). (n = 6 Mean + SD).
doi:10.1371/journal.pone.0106653.g001
Extended Latanoprost Release from Commercial Contact Lenses
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The Role of Live Cells
To study the importance of metabolically active cells, which not
only provide a physical barrier to drug permeation, but also are
able to transfer and metabolize the drug, a set of experiments was
designed to compare latanoprost release from the galyfilcon A
silicone hydrogel material through a fixed and a live monolayer
corneal model. In the fixed monolayer, cells are dead and thus
metabolism of the drug cannot occur.
Figure 2. Comparison of latanoprost release from silicone hydrogels in no-cells model. Release from three silicone hydrogel contact lens
materials in PBS as well as release from galyfilcon A in KSFM (Keratinocyte Serum Free Medium) is shown. Lenses were soaked for 24 hours in drug
solution (131mg=mL) and then overlayed on the model for 24 hours. Aliquots were taken at specific times from the lower compartment and
concentrations were measured using EIA. (n = 3 Mean + SD).
doi:10.1371/journal.pone.0106653.g002
Figure 3. Time course of latanoprost release from senofilcon A in the three in vitro models. Lenses were soaked for 24 hours in drug
solution (131mg=mL) and then overlayed on the model for 24 hours. Aliquots were taken at specific times from the lower compartment and
concentrations were measured using EIA. Daily dose line represents the amount of the administered latanoprost for a glaucoma patient [46]. No-Cell
Model: Cell culture inserts (PET membrane) without cells, Monolayer Model: PET insert with a monolayer of human corneal epithelial cells, Multilayer
Model: PET insert with a multilayer of human corneal epithelial cells (stratified culture). *Significantly different from in vitro models with cells
(pv0:001). (n = 6 Mean + SD).
doi:10.1371/journal.pone.0106653.g003
Extended Latanoprost Release from Commercial Contact Lenses
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As shown in Fig. 6, in the presence of fixed (dead) cells, the
amount of latanoprost that was released from the soaked galyfilcon
A lens and diffused through the monolayer was lower in the
presence of paraformaldehyde-fixed cells when compared to
metabolically-active cells. These results clearly highlight the
importance of the metabolism and transportation in in vitro
model of drug releasing materials.
Discussion
This study was undertaken to determine the impact of the
presence of cells in in vitro models of drug releasing materials. The
cells used in these experiments, HPV-immortalized corneal
epithelial cells have been used previously by Griffith et. al. for
corneal constructs and have been shown to exhibit key physiolog-
ical functions and biochemical marker expression of corneal
epithelial cells [38].
Figure 4. Time course of latanoprost release from four contact lens materials through the monolayer model. Lenses were soaked for
24 hours in drug solution (131mg=mL) and then overlayed on the model for 24 hours. Aliquots were taken at specific times from the lower
compartment and concentrations were measured using EIA. Daily dose line represents the amount of the administered latanoprost for a glaucoma
patient [46]. No-Cell Model: Cell culture inserts (PET membrane) without cells, Monolayer Model: PET insert with a monolayer of human corneal
epithelial cells, Multilayer Model: PET insert with a multilayer of human corneal epithelial cells (stratified culture). *Significantly different from in vitro
models with cells (pv0:001). (n = 6 Mean + SD).
doi:10.1371/journal.pone.0106653.g004
Table 2. Latanoprost Free-Acid Release from Tested Commercial Contact Lenses after 24 Hours.
Contact Lens Material No-Cells Model Monolayer Model Multilayer Model
Release Percentage Release Percentage Release Percentage
½mg=lens of Release{ (%) ½mg=lens of Release{ (%) ½mg=lens of Release{ (%)
Galyfilcon A 0:28+0:14 0:15+0:08 2:71+1:21* 1:47+0:66* 2:79+0:96*
1:51+0:52*
Senofilcon A 0:40+0:11 0:22+0:06 2:86+1:71* 1:55+0:93* 3:50+1:71*
1:90+0:93*
Omafilcon A 4:47+1:58# 10:13+3:59# 6:96+1:26#* 15:77+2:85#* 7:30+1:88#*
16:53+4:25#*
Balafilcon A 0:25+0:08 0:13+0:04 1:71+1:09* 0:90+0:57* 1:93+0:84*
1:01+0:44*
n = 6, Mean + Standard Deviation. Concentration of latanoprost were measured using EIA.
No-Cell Model: Cell culture inserts (PET membrane) without cells, Monolayer Model: PET insert with a monolayer of human corneal epithelial cells, Multilayer Model: PET
insert with a multilayer of human corneal epithelial cells (stratified culture).
{The release as a percentage of uptake has been calculated based on the ratio of the released concentration over the sorbed amount.
#Significantly different from other contact lens materials (silicone hydrogel) (pv0:001).
*Significantly different from the amount released by respective materials in the no-cells model (pv0:001).
doi:10.1371/journal.pone.0106653.t002
Extended Latanoprost Release from Commercial Contact Lenses
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Our initial release experiments with drug soaked contact lens
material in the absence of cells provided results similar to many
others, ([11,12,18,20,22]) showing a mechanism of a first order
release. The limited amount of drug that was released in our fixed
volume model is likely the result of the high partition ratios of the
latanoprost between the contact lens material and the aqueous
solutions. Furthermore, our results from the no-cells model suggest
that latanoprost has a lower affinity toward PBS compared to
KSFM. The better solubility of latanoprost in KSFM compared to
PBS is likely due to the difference in composition, such as the
presence of growth factors and other ionic compounds in the
culture medium which are absent in the buffered saline solution.
While, in our experiments, the nature of the medium was found to
have a statistically significant impact on release in the no-cell
model, the actual improvement in drug release is actually
insignificant when compared to the in vitro models with cells.
Significantly higher drug release and diffusion were observed in
the presence of cells. Due to their hydrophobicity, ester
prostaglandin analogues, such as the latanoprost prodrug, have a
greater chance of diffusion through the hydrophobic corneal
epithelium [43]. Furthermore, metabolism will also play a role in
the presence of live (metabolically active) cells, since the
latanoprost prodrug is expected to be metabolized by cells
[27,29,30,46] before diffusion through the cell layer. The
Figure 5. Time course of latanoprost free-acid release from senofilcon A in No-Cell and Monolayer in vitromodels. Lenses were soaked
for 24 hours in drug solution (131mg=mL) and then overlayed on the model for 24 hours. Aliquots were taken at specific times from the lower
compartment and concentrations were measured using EIA. No-Cell Model: Cell culture inserts (PET membrane) without cells, Monolayer Model: PET
insert with a monolayer of human corneal epithelial cells. Daily dose line represents the amount of the administered latanoprost for a glaucoma
patient [46]. *Significantly different from in vitro models with cells (pv0:001). (n = 3 Mean + SD).
doi:10.1371/journal.pone.0106653.g005
Table 3. Latanoprost Free-Acid Release from Tested Commercial Contact Lenses after 24 Hours.
Contact
Lens
Material Release Model ½mg=lens
No-Cells Monolayer Multilayer
Galyfilcon
A
3:76+1:32 3:27+1:10 2:56+0:46
Senofilcon A 3:06+0:99 1:94+0:56
2:27+0:66
Omafilcon A 2:94+1:73 3:14+1:62
2:05+1:42
Balafilcon
A
5:45+1:76$ 3:65+0:27$ 6:26+2:71$
n = 3, Mean + Standard Deviation. Concentration of latanoprost free-acid were measured using EIA.
No-Cell Model: Cell culture inserts (PET membrane) without cells, Monolayer Model: PET insert with a monolayer of human corneal epithelial cells, Multilayer Model: PET
insert with a multilayer of human corneal epithelial cells (stratified culture).
$Significantly different from other lens materials (pƒ0:025).
doi:10.1371/journal.pone.0106653.t003
Extended Latanoprost Release from Commercial Contact Lenses
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metabolized product, the latanoprost free-acid, has a smaller
partition ratio and is more water soluble when compared to
latanoprost. Therefore, the presence of cells will improve the drug
diffusion rate. A layer of cells will also improve drug release from
the contact lens material by maintaining the concentration
gradient between the lens and the solution above the cells through
metabolism of the latanoprost.
A recent study showed that the nonmetabolized (ester) form of
latanoprost contributed to only 4% of the total drug diffused
through an in vitro corneal model and that no detectable amount
of ester form of the latanoprost was observed in an ex vivo model
[26]. We may thus assume that the majority of the diffused drug
through the in vitro corneal models with cells is the free-acid form.
Different latanoprost release profiles were observed among the
hydrogel contact lens materials tested. Compared to the silicone
hydrogel materials, the high release of latanoprost from omafilcon
A in spite of the lower drug uptake may be explained by the low
affinity of the latanoprost (an hydrophobic compound) toward the
omafilcon A contact lens material, which is a high water content
hydrogel. The large partition ratio results in a low uptake by this
material when soaking in aqueous solution of hydrophobic drugs,
as well as relatively fast release rates in the release solution.
Using latanoprost esterified form, i.e. the active drug com-
pound, latanoprost free-acid, affected results in all models. Higher
water solubility of the latanoprost free-acid led to higher amounts
of drug being released from the silicone hydrogel lens materials in
the no-cell model. As a more polar molecule, latanoprost free-acid
has a lower partition ratio between the hydrophobic silicone
hydrogel contact lens materials and the aqueous solution when
compared to latanoprost. While higher amounts of latanoprost
free-acid were released in the no-cell model, lower releases were
observed in the presence of cells. With latanoprost free-acid,
epithelial cells now act as a barrier against the diffusion of the
latanoprost free-acid, and hence limit the diffusion of the
hydrophilic drug.
As one compares the latanoprost and latanoprost free-acid
release results, it becomes evident that similar drug release profiles
cannot be obtained by replacing the prodrug with the drug, even
in the no-cell model. Not only are the amounts released
significantly different by an order of magnitude, but while all
silicone hydrogel materials released similar amounts of latano-
prost, balafilcon A released significantly more latanoprost free-acid
compared to the other two silicone hydrogels. The balafilcon A/
latanoprost free-acid results are likely due to the fact that
balafilcon A material has an overall net negative charge due to
the incorporation of some acidic material components [46] and its
surface charge increases the hydrodynamic attributes of the
material [47], therefore increasing the role of adsorption of the
hydrophilic drug on the surface of the contact lens during the
uptake process and its subsequent release in solution. Nevertheless,
taken together, our latanoprost free-acid results highlight the
relevance of using in vitro models with cells when studying release
of a prodrug that requires to be metabolized before diffusion
through the tissue to the site of treatment.
Due to the lack of previous in vitro studies on prostaglandin
analogues, our results can only be compared to the release of drugs
from the contact lens materials with similar size and hydropho-
bicity. Previous in vivo studies have shown a prolonged release of
relatively hydrophobic drugs such as ketotifen [21] and lome-
floxacin [23], however such release profiles could not be replicated
in vitro using a fixed volume release model [12,22]. The extended
release of latanoprost observed in the monolayer and multilayer in
vitro models correlates well with the extended release profiles of
the hydrophobic drugs observed in vivo [21,23]. The release
results of latanoprost in the no-cells model is also comparable to
the release results of hydrophobic compounds in fixed volume
solution [12,22]. The significant role of cell metabolism and
transport was further demonstrated using fixed (metabolically
inactive) cells. Taken together, our results suggest that the absence
of cells in in vitro models of drug release likely contributes to the
Figure 6. Time course of latanoprost release from galyfilcon A contact lens through live and dead monolayer models. Cells were
killed by fixing in Paraformaldehyde. Lenses were soaked for 24 hours in drug solution (131mg=mL) and then overlayed on the model for 24 hours.
Release experiments through fixed monolayer were conducted in two separate dates (n = 2, Mean + SD). The results were compared to release
through monolayer models, (n = 6 Mean + SD).
doi:10.1371/journal.pone.0106653.g006
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contradiction between these in vitro and in vivo studies [12,21–
23].
Conclusion
Poor release results from commercially available contact lens
materials soaked in hydrophobic compounds such as latanoprost
have been obtained with fixed volume release models similar to the
no-cells model used here. However, we have demonstrated, using
drug-soaked silicone hydrogel materials, that the amount of drug
diffusing through an in vitro corneal model is in the order of
2{3mg over a period of 24 hours, which is comparable to the
1:5mg of drug in every drop of the commercial latanoprost. Our
results emphasize the importance of the presence of cells when
characterizing the release of drug-delivery materials and demon-
strate how experimental in vitro models have a significant impact
on the outcomes of testing ophthalmic drug delivery materials.
Our in vitro study suggests that silicone hydrogels have the
potential to deliver latanoprost effectively over an extended period
of time.
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